Stock Ratings / Health Care / SILO / insiders

APVO (46) SBFM (44) PPCB (36) PRFX (39) ⌘ Pro Terminal →

Silo Pharma Inc. (SILO) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Is SILO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Silo Pharma Inc. (NASDAQ: SILO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $1.25 (-6.72% 1D, market cap $2.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SILO ranks #1015 in composite RQD confidence.

Q: How does SILO compare to APVO and SBFM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SILO carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 38.6%, and ROIC of -35.0%. By comparison, APVO (Aptevo Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and SBFM (Sunshine Biopharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.4%, cap $2.5M). Among the 5-stock peer group, SILO leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for SILO?

Per SILO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001514183), Silo Pharma Inc. generated $72.1K in revenue (0.0% YoY), -$4.2M in net income, and -$4.7M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is SILO trading relative to its 50-day, 200-day, and 52-week technical levels?

SILO last traded at $1.25 (-6.72% on volume of 15,487 shares), positioning the stock -28.98% below its 50-day simple moving average ($1.76) and -72.59% below its 200-day simple moving average ($4.56). Across its 52-week range of $1.10 to $10.43, SILO sits at the 1.6% percentile with a 14-day RSI of 34.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.09 to $1.41).

Q: Are SILO insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SILO leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$1.25 -6.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.23

Silo Pharma Inc. (SILO) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $2.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.23 (-1.40%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-17.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SILO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (19/100 Composite)

🔍 WHY SILO SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+8/20 pts (42% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.1 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (26% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.47-19.7% Next Q

Q2 (-2Q)

Grade E$1.18+0% Next Q

Q3 (-1Q)

Grade E$1.18+5.9% Next Q

Current

Grade E$1.25-12% Hist 90D α

Trajectory: E (27) → E (19)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SILO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SILO currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.76) and Max Pain ($1.31) forces dealer call-delta covering toward $10.95.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SILO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SILO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 19%NO 81%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SILO Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SILO)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SILO. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SILO)

✓Walkthrough of SILO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SILO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -81.15%⚡ TESTING RESISTANCE

2026-10-30O $1.24H $1.25L $1.20C $1.25VOL 12.0K

RES: $1.26SUP: $0.40SMA50: $1.76SMA200: $4.56

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SILO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SILO Butterfly Map → + Track SILO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. 0.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SILO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SILO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SILO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SILO)

Health Care Rank #1015 of 1016 ⚔️ APVO vs SILO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SILO vs. APVO, SBFM, PPCB, PRFX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Silo Pharma Inc. (SILO) ranks #1015 by composite RQD confidence (19/100, grade E) and #991 by equity capitalization ($2.4M). Within this direct 5-issuer industry benchmark cohort, SILO leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. APVO currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with SILO at 19/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SILO ACTIVE Silo Pharma Inc.	E	19/100	—	38.6%	-35.0%	-6.72%	$2.4M	Benchmark Subject
APVO Aptevo Therapeutics Inc.	D	46/100	—	—	-35.0%	+4.62%	$2.5M	/apvo-vs-silo →
SBFM Sunshine Biopharma Inc.	D	44/100	—	33.8%	-21.4%	+7.07%	$2.5M	/sbfm-vs-silo →
PPCB Propanc Biopharma Inc.	D-	36/100	—	—	-35.0%	0.00%	$2.2M	/ppcb-vs-silo →
PRFX PRF Technologies Ltd.	D-	39/100	—	-30.0%	-35.0%	-3.86%	$2.6M	/prfx-vs-silo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001514183

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Silo Pharma Inc. (SILO) reported GAAP revenue of $72.1K (0.0% vs. FY2024 revenue of $72.1K , and 0.0% cumulative change since FY2023) , GAAP net income of -$4.2M, operating cash flow of -$4.7M, and free cash flow of -$4.7M (-21.6% YoY). On the balance sheet, SILO closed FY2025 with $7.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$72.1K	-$4.2M	-$4.7M	-$4.7M	$7.6M	—
FY2024 (FY)	2024-12-31	$72.1K	-$4.4M	-$3.8M	-$3.8M	$7.4M	—
FY2023 (FY)	2023-12-31	$72.1K	-$3.7M	-$3.2M	-$3.2M	—	—

3. SILO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SILO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Silo Pharma Inc. (NASDAQ: SILO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $1.25 (-6.72% 1D, market cap $2.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SILO ranks #1015 in composite RQD confidence.

How does SILO compare to APVO and SBFM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SILO carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 38.6%, and ROIC of -35.0%. By comparison, APVO (Aptevo Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and SBFM (Sunshine Biopharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.4%, cap $2.5M). Among the 5-stock peer group, SILO leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SILO?

Per SILO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001514183), Silo Pharma Inc. generated $72.1K in revenue (0.0% YoY), -$4.2M in net income, and -$4.7M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SILO trading relative to its 50-day, 200-day, and 52-week technical levels?

SILO last traded at $1.25 (-6.72% on volume of 15,487 shares), positioning the stock -28.98% below its 50-day simple moving average ($1.76) and -72.59% below its 200-day simple moving average ($4.56). Across its 52-week range of $1.10 to $10.43, SILO sits at the 1.6% percentile with a 14-day RSI of 34.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.09 to $1.41).

SILO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are SILO insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SILO leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: SILO RQD Cockpit SILO 12M Forecast SILO Earnings & Move SILO Dividends & DRIP SILO Insiders & 13F SILO Whale Options SILO Profit Sankey SILO News & Why